Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

3rd Immunotherapy of Cancer Conference (ITOC3) /
T cells expressing two additional receptors (TETARs) for the use in a multiple- hit immunotherapy

21st - 23rd Mar 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.04.16
Views: 1380

Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany

Dr Gerold Schuler speaks with ecancertv about his lab's variation on CAR T Cells: TETARs - CD8 T Cells expressing two additional antigens.

In trials, the addition of novel receptors to T Cells via RNA transfection has been used to create modified T Cells expressing novel antigen binding configurations, with theoretically unlimited combinations and no risk to host models. 

Further trials are ongoing.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation